Skip to main content

Table 2 Clinical characteristics and outcome

From: Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

 

Overall

(N = 10)

Stable disease

(N = 4)

Progressive disease

(N = 6)

Uptake Grade ≥ 3

7/10 (70%)

4/4 (100%)

3/6 (50%)

Uptake Grade < 3

3/10 (30%)

0/0 (0%)

3/6 (50%)

SSTR2a tumour expression

4/10 (40%)

4/4 (100%)

0/6 (0%)

Loss of correlation CT

3/6 (50%)

0/4 (0%)

3/6 (50%)

  1. Abbreviations: Calcitonin, CT; Grade 3: uptake > normal liver uptake; N, number; SSTR, somatostatin receptor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us